Angiogenesis and cancer;Angiogenese et cancer

Bulletin du Cancer

Volumn 84, Issue 9, 1997, Pages 885-890

  Bikfalvi, Andreas ^a   Javerzat, Sophie ^a   Perollet, Catherine ^a   Savona, Catherine ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

angiogenesis; growth factors and inhibitors; tumor invasion

Indexed keywords

ANTIESTROGEN; CALCIUM ION; GROWTH FACTOR; GROWTH INHIBITOR; HEPARIN; HEPARIN LYASE; PROTAMINE SULFATE; SURAMIN; THALIDOMIDE; GROWTH PROMOTOR;

ANGIOGENESIS; CANCER; HUMAN; REVIEW; CANCER INVASION; GENETICS; METABOLISM; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

GROWTH SUBSTANCES; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0031219019     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989 ; 339 : 58-61.
2. Gospodarowicz, Cheng J, Lui GM, Baird A, Bohleu P. Isolation of brain fibroblast growth factor by heparin-sepharose affinity chromatography : identity with pituitary growth factor. Proc Natl Acad Sci USA 1984 ; 81 : 6963-7.
3. Montesano B, Vassali JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986 ; 83 : 7297-300.
4. Moscatelli D, Presta M, Joseph-Silverstein J, Rifkin DB. Both normal and tumor cells produce basic fibroblast growth factor. J Cell Physiol 1986 ; 129 : 273-6.
5. Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989 ; 56 (3) : 345-55.
6. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin : a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994 ; 79 : 315-28.
7. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin : an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997 ; 88 : 277-85.
8. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996 ; 86 : 353-64.
9. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Reviews 1997 ; 18 : 25.
10. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2 (FGF-2). Endocrine Reviews 1997 ; 18 : 26-45.
11. Hanahan D. Heritable formation of pancreatic beta-cell tumors in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 1985 ; 315 : 115-22.
12. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994 ; 265 : 1582-4.
13. Volpert OV, Stellmach V, Bouck N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat 1995 ; 36 : 119-26.
14. Vermeulen PB, Roland L, Mertens V, et al. Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma. Microvasc Res 1996 ; 51 : 164-74.
15. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor hypoxia-inducible factor-1. Mol Cell Biol 1995 ; 16 : 4604-13.
16. Tagaki H, King GL, Robinson GS, Ferrara N, Aiello LP. Hypoxic induction of VEGF is mediated by adenosine through A2 receptors and elevation of cAMP in retinal pericytes and endothelial cells. Invest Ophtalmol Vis Sci 1996 ; 37 : 2165-76.
17. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-scr activation. Nature 1995 ; 375 : 577-81.
18. Olofsson B, Pajusola K, Kaipainen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996 ; 93 : 2576-81.
19. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2 receptor tyrosine kinases). EMBO J 1996 ; 15 : 290-8.
20. Cunningham SA, Waxham MN, Arrate PM, Brock TA. Interaction of the Flt-& tyrosine kinase receptor with the p85 subunit of the phosphatidyl 3-kinase. J Biol Chem 1995 ; 35 : 20254-7.
21. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Differential signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994 ; 269 : 26988-95.
22. Barleon B, Sozzani S, Zhou D, Weich H, Mantovani A, Marmé D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor FLT-1. Blood 1996 ; 87 : 3336-43.
23. Keyt BA, Nguyen HV, Berleau LT, et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 1996 ; 271 : 5638-46.
24. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative FLK-1 mutant. Nature 1994 ; 367 : 576-8.
25. Shalaby F, Rossant J, Yamagushi TP, et al. Failure of blood island formation and vasculogenesis in FLK-1 deficient mice. Nature 1995 ; 376 : 62-6.
26. Fong GH, Rossant J, Gerteinstein M, Breitman MI. Role of the FLT-1 receptor tyrosine kinase in regulating the assembly of the vascular endothelium. Nature 1995 ; 376 : 66-70.
27. Carmeliet P, Ferreira V, Breir G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996 ; 380 : 435-9.
28. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Narure 1996 ; 380 : 439-42.
29. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids : implications for tumor angiogenesis. Proc Natl Acad Sci USA 1995 ; 92 : 768-72.
30. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996 ; 56 : 2013-6.
31. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996 ; 93 : 14765-70.
32. Smallwood PM, Munoz-Sanjuan I, Tong P, et al. Fibroblast growth factor (FGF) homologous factors : new members of the FGF family implicated in nervous system development. Proc Natl Acad Sci USA 1996 ; 93 : 9850-7.
33. Bikfalvi A, Klein S, Pintucci G, Quarto N, Mignatti P, Rifkin DB. Differential modulation of cell phenotype by different molecular weight forms of basic fibroblast growth factor : possible intracellular signaling by the high molecular weight forms. J Cell Biol 1995 ; 129 : 233-43.
34. Klein S, Giancotti FG, Presta M, Albeda SA, Buck CA, Rifkin DB. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell 1993 ; 4 : 973-82.
35. Klein S, Bikfalvi A, Birkenmeier T, Giancotti FG, Rifkin DB. Modulation of integrins by endogenous 18 kDa FGF-2. J Biol Chem 1996 ; 271 : 22583-90.
36. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA, Definition of two angiogenic pathways by distinct a integrins. Science 1995 ; 270 : 1500-2.
37. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J Elevated levels of an angiogenic peptide basic fibroblast growth factor in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994 ; 86 : 356-61.
38. Li VW, Folkerth RD, Watanabe H, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet 1994 ; 344 : 82-6.
39. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-Trap expression cloning. Cell 1996 ; 87 : 1161-9.
40. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1 a ligand for the Tie2 receptor, during embryonic angiogenesis. Cell 1996 ; 87 : 1171-80.
41. Cao Y, Ji RW, Davidson D, et al. Kringle domains of human angiostatin : characterization of the antiproliferative activity of angiostatin. 1 Biol Chem 1996 ; 271 : 29461-7.
42. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases : balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995 ; 1 : 149-53.
43. Watson JB, Getzler SB, Mosher DF. Platelet factor-4 modulates the mitogenic activity of basic fibroblast growth factor. J Clin Invest 1994 ; 94 : 261-8.
44. Sasisekharan R, Moses MA, Nugent MA, Cooney CL, Langer R. Heparinase inhibits neovascularisation. Proc Natl Acad Sci USA 1994 ; 91 : 1524-8.
45. Gupta SK, Hassel T, Singh JP. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acid Sci USA 1995 ; 92 : 7799-803.
46. Gagliardi AR, Hennig B, Collins DC. Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. Anticancer Res 1996 ; 16 : 1101-6.
47. Cheng SY, Huang HJS, Nagane M, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996 ; 93 : 8502-7.
48. Parangi S, O'Reilly M, Christofori G, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth Proc Natl Acad Sci USA 1996 ; 93 : 2002-7.